Product Information
MECLIZINE 12.5 MG TABLET is a generic product labeled by Rising Pharma Holdings Inc., priced at $0.0442 per EA under NDC 16571066050. Its NADAC has been published 332 times since May 27, 2020.
FDA first approved this application before 1982. Its Orange Book therapeutic-equivalence code is AA.
The High Outlier badge above means this manufacturer's average price in the Meclizine Hydrochloride market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
12.5 mg/1
Manufacturer
Rising Pharma Holdings Inc.NDC
16571066050
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
MECLIZINE HYDROCHLORIDEApproval Type
Authorized Generic (NDA)
FDA Application
NDA010721FDA Approved
Before 1982
TE Code
AA
On Market Since
1/15/2020
Pharmacological Classes
Price Statistics
The NADAC for MECLIZINE 12.5 MG TABLET has been published 332 times since May 27, 2020, and over the history we have for it it has declined 71.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0442 per EA |
|---|---|
| All-time high | $0.1668 (Jul 15, 2020) |
| All-time low | $0.0418 (Nov 20, 2024) |
| 52-week high | $0.0497 |
| 52-week low | $0.0442 |
| Median price | $0.0709 |
| Average price | $0.0809 |
| Largest weekly change | -29.2% (Nov 20, 2024) |
| Weeks tracked | 332 |
| Tracking since | May 27, 2020 |
Generic Alternatives
The matcher finds 8 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 29% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Rising Pharma Holdings Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Meclizine Hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Antiemetic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of MECLIZINE 12.5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for MECLIZINE 12.5 MG TABLET, manufactured by Rising Pharma Holdings Inc., is $0.0442 per EA (NDC 16571066050), effective Sep 30, 2026.
How has the price of MECLIZINE 12.5 MG TABLET changed over time?
Over the history we have for it, the NADAC for MECLIZINE 12.5 MG TABLET has declined 71.8%. It has been tracked across 332 weekly CMS publications since May 27, 2020.
What are the highest and lowest recorded NADAC prices for MECLIZINE 12.5 MG TABLET?
Since May 27, 2020, the NADAC for MECLIZINE 12.5 MG TABLET has ranged from a low of $0.0418 (Nov 20, 2024) to a high of $0.1668 (Jul 15, 2020), with a median of $0.0709 per EA.
Are there cheaper alternatives to MECLIZINE 12.5 MG TABLET?
Yes. 8 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, MECLIZINE 12.5 MG TABLET, is $0.0313 per EA — about 29% below MECLIZINE 12.5 MG TABLET.
Who manufactures MECLIZINE 12.5 MG TABLET?
MECLIZINE 12.5 MG TABLET (NDC 16571066050) is labeled by Rising Pharma Holdings Inc., and CMS classifies it as a generic product.